Ticlopidine

Summary

Ticlopidine (CHEMBL833) is an approved small-molecule fibrin modulating drug (ATC B01AC05) targeting CYP2B6; indicated across 3 conditions including thrombotic disease and internal carotid artery stenosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B01AC05
• Targets: 1 (CYP2B6)
• Indications: 3 conditions
• Clinical trials: 6
• Chemistry: 263.8 Da · C14H14ClNS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL833
Name	Ticlopidine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5472
ChEBI	CHEBI:9588
ATC	B01AC05
Molecular formula	C14H14ClNS
Molecular weight	263.8
InChIKey	PHWBOXQYWZNQIN-UHFFFAOYSA-N

SMILES: C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl

IUPAC name: 5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine

ChEBI definition: A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Pharmacological roles (ChEBI): fibrin modulating drug, hematologic agent, anticoagulant, platelet aggregation inhibitor, P2Y12 receptor antagonist.

Also known as: Ticlopidin-puren, Ticlopidina, Ticlopidine, SID11112786, SID26751617, SID50085878, SID104171328, ticlopidine, SID144204209, Ticlid, TICLOPIDINE, SID170464698

Parent form; salt/anhydrous children: CHEMBL1717

Patent coverage: 7,945 distinct patent families (30,572 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 30,462 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CYP2B6	CYP2B6	Inhibition	6.7	0.1%	P20813

Broader ChEMBL bioactivity targets: 29 (assay-derived). Sample: Ubiquitin carboxyl-terminal hydrolase 2, Prelamin-A/C, Ferritin light chain, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor.

Bioactivity

ChEMBL activities: 35 potent at pChembl ≥ 5 of 56 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C19	7.4	Potency	39.8	nM	CHEMBL_ACT_4019499
CYP2C19	7.4	AC50	39.81	nM	CHEMBL_ACT_6052076
ADRA2B	6.86	Ki	139	nM	CHEMBL_ACT_7810769
ADRA2A	6.84	Ki	143	nM	CHEMBL_ACT_7810767
ADRA2C	6.77	Ki	171	nM	CHEMBL_ACT_7810771
SIGMAR1	6.75	Ki	179	nM	CHEMBL_ACT_7815020
CYP2B6	6.7	Ki	200	nM	CHEMBL_ACT_6075021
CYP2B6	6.68	IC50	210	nM	CHEMBL_ACT_24925630
ADRA2B	6.52	IC50	304	nM	CHEMBL_ACT_7810768
ADRA2A	6.42	IC50	382	nM	CHEMBL_ACT_7810766
CYP2D6	6.4	Potency	398.1	nM	CHEMBL_ACT_4994276
CYP2D6	6.4	AC50	398.1	nM	CHEMBL_ACT_5988630
SIGMAR1	6.37	IC50	426	nM	CHEMBL_ACT_7815019
CYP1A2	6.3	AC50	501.2	nM	CHEMBL_ACT_6051021
CYP2B6	6.22	IC50	600	nM	CHEMBL_ACT_16637021
CYP2C19	6.17	IC50	667.8	nM	CHEMBL_ACT_7812839
CYP2B6	6.1	Ki	800	nM	CHEMBL_ACT_6075023
ADRA2B	5.97	AC50	1077	nM	CHEMBL_ACT_25143582
ADRA2C	5.96	AC50	1091	nM	CHEMBL_ACT_25147753
ADRA2C	5.93	IC50	1175	nM	CHEMBL_ACT_7810770
ADRA2A	5.92	AC50	1200	nM	CHEMBL_ACT_25219779
CYP2C19	5.89	IC50	1300	nM	CHEMBL_ACT_16621051
ADRA2A	5.81	AC50	1562	nM	CHEMBL_ACT_25155903
CYP2C19	5.48	Ki	3300	nM	CHEMBL_ACT_12163631
ALDH1A1	5.4	Potency	3981	nM	CHEMBL_ACT_4170663
DRD1	5.34	AC50	4600	nM	CHEMBL_ACT_25180400
CYP2D6	5.32	IC50	4800	nM	CHEMBL_ACT_15450958
OPRK1	5.23	AC50	5873	nM	CHEMBL_ACT_25129318
DRD4	5.2	AC50	6267	nM	CHEMBL_ACT_25127352
CYP2D6	5.2	IC50	6293	nM	CHEMBL_ACT_7812843

Target pathways

Aggregated over 1 target gene(s): CYP2B6.

Top Reactome pathways

4 total, by targets touching each:

Pathway	Targets	Genes
Fatty acids	1	CYP2B6
Phase I - Functionalization of compounds	1	CYP2B6
Xenobiotics	1	CYP2B6
CYP2E1 reactions	1	CYP2B6

Dominant GO biological processes

GO term	Targets
xenobiotic metabolic process	1
steroid metabolic process	1
epoxygenase P450 pathway	1
xenobiotic catabolic process	1
ketone metabolic process	1
lipid metabolic process	1
small molecule metabolic process	1

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419
internal carotid artery stenosis	3	MONDO:0005189	EFO:0002615
peripheral arterial disease	3	MONDO:0005386	EFO:0004265

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE3	3
PHASE4	2
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004727	PHASE4	COMPLETED	Antiplatelet Therapy to Prevent Stroke in African Americans
NCT01214941	PHASE4	COMPLETED	Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
NCT00821834	PHASE3	COMPLETED	Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
NCT00862420	PHASE3	COMPLETED	Safety Evaluation of Clopidogrel Sulfate in Patients With Peripheral Arterial Disease
NCT02133989	PHASE3	UNKNOWN	Clopidogrel Resistance and Embolism in Carotid Artery Stenting
NCT03298906	PHASE1	COMPLETED	A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 22 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

44 molecules share ≥1 primary target. Top 44 by shared-target count:

Molecule	Source	Status	Shared targets
MAVACAMTEN	ChEMBL + PubChem	Phase 4 (approved)	CYP2B6
RIFAMPIN	ChEMBL + PubChem	Phase 4 (approved)	CYP2B6
CANNABIDIOL	ChEMBL	Phase 4 (approved)	CYP2B6
CLOPIDOGREL	ChEMBL	Phase 4 (approved)	CYP2B6
ESTRADIOL	ChEMBL	Phase 4 (approved)	CYP2B6
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	CYP2B6
IBRUTINIB	ChEMBL	Phase 4 (approved)	CYP2B6
METHADONE	ChEMBL	Phase 4 (approved)	CYP2B6
PAZOPANIB	ChEMBL	Phase 4 (approved)	CYP2B6
RITONAVIR	ChEMBL	Phase 4 (approved)	CYP2B6
SERTRALINE	ChEMBL	Phase 4 (approved)	CYP2B6
TAMOXIFEN	ChEMBL	Phase 4 (approved)	CYP2B6
THIOTEPA	ChEMBL	Phase 4 (approved)	CYP2B6
TRANYLCYPROMINE	ChEMBL	Phase 4 (approved)	CYP2B6
VORICONAZOLE	ChEMBL	Phase 4 (approved)	CYP2B6
ARTEMISININ	ChEMBL	Phase 3	CYP2B6
CANNABINOL	ChEMBL	Phase 3	CYP2B6
CURCUMIN	ChEMBL	Phase 3	CYP2B6
TEMSAVIR	ChEMBL + PubChem	Phase 2 (approved)	CYP2B6
APINOCALTAMIDE	ChEMBL	Phase 2	CYP2B6
CANNABIDIVARIN	ChEMBL	Phase 2	CYP2B6
DARIGABAT	ChEMBL	Phase 2	CYP2B6
FISOGATINIB	ChEMBL	Phase 2	CYP2B6
INE-963	ChEMBL	Phase 2	CYP2B6
MK-0893	ChEMBL	Phase 2	CYP2B6
PHENCYCLIDINE	ChEMBL	Phase 2	CYP2B6
UDIFITIMOD	ChEMBL	Phase 2	CYP2B6
Abiraterone	PubChem	Approved	CYP2B6
Aprepitant	PubChem	Approved	CYP2B6
Belzutifan	PubChem	Approved	CYP2B6
Cenobamate	PubChem	Approved	CYP2B6
Clozapine	PubChem	Approved	CYP2B6
Erythromycin	PubChem	Approved	CYP2B6
Imatinib	PubChem	Approved	CYP2B6
Methimazole	PubChem	Approved	CYP2B6
Olanzapine	PubChem	Approved	CYP2B6
Olmesartan	PubChem	Approved	CYP2B6
Oritavancin	PubChem	Approved	CYP2B6
Pimozide	PubChem	Approved	CYP2B6
Safinamide	PubChem	Approved	CYP2B6
saxagliptin	PubChem	Approved	CYP2B6
Tecovirimat	PubChem	Approved	CYP2B6
Vorapaxar	PubChem	Approved	CYP2B6
Zanubrutinib	PubChem	Approved	CYP2B6